Jax DiEugenio

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for OncLive. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

Articles

Dr Dreyling on Prior Findings From the ECHO Trial of Acalabrutinib Plus BR in Pretreated MCL

October 15th 2025

Martin Dreyling, MD, discusses prior findings and potential implications of the phase 3 ECHO trial of acalabrutinib plus BR in pretreated MCL.

FDA Approval of TAR-200 Represents Potential Bladder-Sparing Option in BCG-Unresponsive NMIBC

October 15th 2025

Joseph Jacob, MD, MCR, discusses the significance of the FDA approval of TAR-200 for BCG-unresponsive non–muscle-invasive bladder cancer.

Baseline Cardiovascular Assessment, Monitoring Are Crucial With BTK Inhibitors in CLL and Other Hematologic Malignancies

October 14th 2025

A meta analysis found BTK inhibitors carry risks of hypertension, atrial fibrillation, and hemorrhage, underscoring the need for cardiovascular monitoring.

Oncology Experts Preview Key Studies Ahead of the 2025 ESMO Congress

October 13th 2025

Leading experts across oncology specialties preview the key studies and data they are most anticipating ahead of the 2025 ESMO Congress.

Olaparib Withstands the Test of Time With Long-Term Data Supporting Its Role in Ovarian Cancer Treatment

October 13th 2025

Kevin Elias, MD, discusses the role of olaparib in the management of ovarian cancer.

Dr Sweis on the Mechanism of Action of XmAb819 in RCC

October 10th 2025

Randy F. Sweis, MD, explains the mechanism of action of the ENPP3/CD3–targeted bispecific T-cell engager XmAb819 in renal cell carcinoma.

Removal of REMS Requirements Could Help Streamline CAR T-Cell Therapy Access in Hematologic Cancer Care

October 10th 2025

The removal of REMS programs for approved CAR T-cell therapies could enable improved access and streamlined management of hematologic malignancies.

Dr Elias on Efficacy Data With Olaparib in BRCA-Mutated Ovarian Cancer

October 10th 2025

Kevin Elias, MD, discusses the SOLO-1 and SOLO-2 trials, which evaluated olaparib in newly diagnosed and relapsed BRCA-mutated ovarian cancer.

Ibrutinib Plus Rituximab Shows PFS Benefit Over Chemoimmunotherapy in Untreated MCL

October 10th 2025

Ibrutinib plus rituximab showed a progression-free survival benefit vs standard chemoimmunotherapy in older patients with untreated mantle cell lymphoma.

Daratumumab/Lenalidomide With Limited Dexamethasone Displays Feasibility in Older/Frail Newly Diagnosed Myeloma

October 9th 2025

Daratumumab plus lenalidomide, with reduced exposure to dexamethasone, led to a PFS improvement in frail, newly diagnosed multiple myeloma.

ONO-4578 Plus Nivolumab/Chemo Improves PFS in HER2– Advanced Gastric Cancer

October 9th 2025

ONO-4578 plus nivolumab and chemotherapy improved PFS in HER2-negative advanced gastric cancer.

FDA Grants Fast Track Designation to ADCE-D01 for Soft Tissue Sarcoma

October 9th 2025

The FDA granted fast track designation to ADCE-D01 for the treatment of soft tissue sarcoma.

Poor Response Rates Persist After Progression on Brexu-Cel in Mantle Cell Lymphoma

October 9th 2025

Patients with MCL who relapsed after brexu-cel had poor survival outcomes, underscoring the need for effective post–CAR T-cell therapy strategies.

Eribulin Plus Pyrotinib Displays Efficacy in Trastuzumab-Resistant HER2+ Breast Cancer

October 9th 2025

Eribulin with pyrotinib was safe and active in patients with HER2-positive advanced breast cancer who were resistant to treatment with trastuzumab.

Dr Dreyling on the Rationale for Adding Acalabrutinib to BR in High-Risk MCL

October 8th 2025

Martin Dreyling, MD, discusses why adding acalabrutinib to bendamustine plus rituximab may benefit patients with pretreated, high-risk MCL.

Dr Saad on the Rationale for the PEACE-3 Trial in mCRPC With Bone-Predominant Disease

October 8th 2025

Fred Saad, MD, discusses the rationale behind the long-term safety analysis for radium-223 dichloride and enzalutamide in metastatic castration-resistant prostate cancer with bone-predominant disease.

FDA Approves Adjuvant Cemiplimab for Cutaneous Squamous Cell Carcinoma

October 8th 2025

The FDA approved cemiplimab-rwlc for the adjuvant treatment of cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation.

Inside the Most Anticipated Genitourinary Cancer Abstracts: What to Watch at ESMO 2025

October 8th 2025

Experts in genitourinary oncology share key insights on the most anticipated data and abstracts expected to shape discussions at the 2025 ESMO Congress.

FDA Issues CRL for Dasatinib in Chronic Myeloid Leukemia

October 8th 2025

The FDA has issued a CRL for dasatinib, a next-generation formulation of a protein kinase inhibitor, for the treatment of patients with chronic myeloid leukemia.

Dr Sampath on the Safety of Consolidative Radiotherapy Plus Osimertinib in Advanced EGFR-Mutant NSCLC

October 7th 2025

Sagus Sampath, MD, discusses the safety profile of consolidative radiotherapy administered in conjunction with osimertinib in advanced EGFR-mutant NSCLC